scholarly journals Leishmania infantum-induced primary and challenge infections in rhesus monkeys (Macaca mulatta): a primate model for visceral leishmaniasis

Author(s):  
R. Porrozzi ◽  
M.S. Pereira ◽  
A. Teva ◽  
A.C. Volpini ◽  
M.A. Pinto ◽  
...  
1977 ◽  
Vol 56 (12) ◽  
pp. 1586-1598 ◽  
Author(s):  
Arthur N. Bahn ◽  
Irving L. Shklair ◽  
James A. Hayashi

The feasibility of immunizing monkeys with enzymes from oral streptococci in an attempt to reduce dental caries was investigated. Forty rhesus monkeys, Macaca mulatta, were used. Cariogenic streptococci, S mutans, were implanted into all the monkeys' mouths. There was no pathological effect resulting from immunization. Of the 40 animals, 30 retained the implanted flora throughout the experiment; the remaining 10 were reimplanted until the streptococci remained. In six months, gross carious lesions were evident with plaque. Inhibitors present in the monkey sera after immunization inhibited glucosyltransferase, fructosyltransferase, and neuraminidase activzties. It was presumed the inhibitors were antibodies. There was a reduction of 68.6% in the total carious lesions in the animals immunized intraorally with glucosyltransferase, 62.4% reduction in those injected with fructosyltransferase, and 57.4% reduction in total lesions in those immunized with glycosidic hydro lases after 19 months, as compared to the control group. There were no gross lesions apparent in the group immunized with glycosidic hydrolases. It appears that immunization with enzymes significantly reduces caries and is feasible in a primate model.


2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 131-132
Author(s):  
Ricki Colman ◽  
Tamara Tchkonia ◽  
Tamar Pirtskhalava ◽  
Nino Giorgadze ◽  
Larissa Prata ◽  
...  

Abstract Aging is the biggest risk factor for the most serious chronic diseases and disabilities. Cellular senescence, a state in which cells stop dividing but release factors that damage other cells, may contribute to both age-related and chronic diseases. Removal of senescent cells from aged mice has been shown to delay aging and age–related disabilities. Our goal was to determine the ability of potential senolytic agents to remove senescent cells in a primate model. Several agents and combinations were tested including Fisetin, Navitoclax, combined Dasatinib and Quercetin, and combined Dasatinib and Fisetin. Here we describe the Dasatinib and Fisetin trial. Dasatinib is an FDA approved oral anticancer drug that has been used to treat chronic myelogenous leukemia in humans. Fisetin is a flavonoid that can be found in many plants, particularly strawberries, and acts as a coloring agent. After baseline measurements, six older (mean age=21 years) female rhesus monkeys (Macaca mulatta) were given a combined oral dose of Dasatinib (5 mg/kg) and Fisetin (100 mg/kg) on two consecutive days. Animals were additionally assessed at 1- and 7-weeks following dosing. At 7 weeks post dosing, there were fewer (p<0.05) p16+ cells in the epidermis compared to baseline. Similarly, there was a reduction (p<0.05) in p21+ cells in the epidermis at 1- and 7-weeks post dosing compared to baseline. There were no negative outcomes associated with treatment. This study provides preliminary evidence for the senolytic potential of combined Dasatinib and Fisetin treatment and indicates that pharmacological mitigation of age-related changes is possible.


2013 ◽  
Author(s):  
Emily Kathryn Brown ◽  
Victoria L. Templer ◽  
Robert R. Hampton

Primates ◽  
1976 ◽  
Vol 17 (4) ◽  
pp. 543-546 ◽  
Author(s):  
G. Mitchell ◽  
Jody Gomber

Sign in / Sign up

Export Citation Format

Share Document